North America pharmaceutical contract research organization (CRO) market is projected to grow by 9.0% annually in the forecast period and reach $37.61 billion by 2030, driven by the increasing incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity.
Highlighted with 59 tables and 44 figures, this 132-page report 鈥淣orth America Pharmaceutical Contract Research Organization (CRO) 麻豆原创 2021-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity鈥 is based on comprehensive research of the entire North America pharmaceutical contract research organization (CRO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2030 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥 麻豆原创 Structure
鈥 Growth Drivers
鈥 Restraints and Challenges
鈥 Emerging Product Trends & 麻豆原创 Opportunities
鈥 Porter鈥檚 Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical contract research organization (CRO) market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Country.
Based on Service, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section.
鈥 CRO for Pre-clinical Development
鈥 CRO for Phase I Trials
鈥 CRO for Phase II Trials
鈥 CRO for Phase III Trials
鈥 CRO for Phase IV Trials
鈥 Laboratory Services
鈥 Consulting Services
鈥 Data Management Services
Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section.
鈥 Infectious Diseases
鈥 Oncology
鈥 Metabolic Disorders
鈥 Cardiovascular Disorders
鈥 Central Nervous System
鈥 Respiratory Disorders
鈥 Gastrointestinal Disorders
鈥 Other Therapeutic Applications
By End User, the North America market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section.
鈥 Pharmaceutical & Biopharmaceutical Companies
鈥 Medical Device Companies
鈥 Academic Institutes
Geographically, the following national/local markets are fully investigated:
鈥 U.S.
鈥 Canada
鈥 Mexico
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2021-2030. The breakdown of key national markets by Service, Therapeutic Application, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co., Ltd.
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co., Ltd.
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co., Ltd.
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of 麻豆原创 Research Methodology 11
1.2.2 麻豆原创 Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 麻豆原创 Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 麻豆原创 Overview and Dynamics 20
2.1 麻豆原创 Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the 麻豆原创 23
2.2 Major Growth Drivers 25
2.3 麻豆原创 Restraints and Challenges 33
2.4 Emerging Opportunities and 麻豆原创 Trends 36
2.5 Porter鈥檚 Fiver Forces Analysis 40
3 Segmentation of North America 麻豆原创 by Service 44
3.1 麻豆原创 Overview by Service 44
3.2 CRO for Pre-clinical Development 46
3.3 CRO for Phase I Trials 47
3.4 CRO for Phase II Trials 48
3.5 CRO for Phase III Trials 49
3.6 CRO for Phase IV Trials 50
3.7 Laboratory Services 51
3.8 Consulting Services 52
3.9 Data Management Services 53
4 Segmentation of North America 麻豆原创 by Therapeutic Application 54
4.1 麻豆原创 Overview by Therapeutic Application 54
4.2 Infectious Diseases 56
4.3 Oncology 57
4.4 Metabolic Disorders 58
4.5 Cardiovascular Disorders 59
4.6 Central Nervous System 60
4.7 Respiratory Disorders 61
4.8 Gastrointestinal Disorders 62
4.9 Other Therapeutic Applications 63
5 Segmentation of North America 麻豆原创 by End User 64
5.1 麻豆原创 Overview by End User 64
5.2 Pharmaceutical & Biopharmaceutical Companies 66
5.3 Medical Device Companies 67
5.4 Academic Institutes 68
6 North America 麻豆原创 2019-2030 by Country 69
6.1 Overview of North America 麻豆原创 69
6.2 U.S. 72
6.3 Canada 75
6.4 Mexico 77
7 Competitive Landscape 79
7.1 Overview of Key Vendors 79
7.2 New Product Launch, Partnership, Investment, and M&A 83
7.3 Company Profiles 84
Charles River Laboratories 84
CMIC Co. Ltd 86
Covance Inc. 88
Hangzhou Tigermed Consulting Co., Ltd. 92
ICON Plc 95
IQVIA Holdings Inc. 98
LSK North America Pharma Service Co., Ltd. 102
Novotech Pty Ltd 104
PAREXEL International Corporation 106
Pharmaceutical Product Development LLC (PPD) 110
PRA Health Sciences Inc. 112
Quanticate Ltd 114
Samsung Bioepis Co., Ltd. 116
SGS SA (SGS Life Sciences) 118
Syneos Health Inc. 121
WuXi AppTec Inc. 124
8 Investing in North America 麻豆原创: Risk Assessment and Management 126
8.1 Risk Evaluation of North America 麻豆原创 126
8.2 Critical Success Factors (CSFs) 129
Related Reports and Products 132
Selected Key Players:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co., Ltd.
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co., Ltd.
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co., Ltd.
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.